T2 Biosystems Announces Research and Development Collaboration with Bayer to Advance Drug Monitoring and Biomarker Discovery for Blood Coagulation Disorders
The sensitivity of T2MR in blood coagulation (hemostasis) research allows for the rapid and comprehensive monitoring of drug side effects in animal models and patients.
"We are very enthusiastic about our collaboration with Bayer and the important validation it represents for our T2MR technology in the field of hemostasis," said John McDonough, chief executive officer of T2 Biosystems. "Together with Bayer, we look forward to continuing the exploration of the clinical potential of our platform to provide improved patient care in this area of significant unmet need.”
The companies have been working together for the last year and recently extended the collaboration to include a number of pre-clinical and early clinical programs. This collaboration will enable
About T2MR
T2MR is a diagnostic detection method utilizing miniaturized magnetic resonance technology that measures how water molecules react in the presence of magnetic fields. The T2MR technology platform offers a fast, simple and sensitive alternative to existing diagnostic methodologies. T2MR technology powers all of the diagnostic innovation at
About T2MR in Hemostasis
The first stage of wound healing, hemostasis, is a complex interaction of proteins and biochemical signals regulating the balance between bleeding and blood clotting. Patients with impaired hemostasis are either unable to promote the formation of blood clots to stabilize excessive bleeding or are hypercoaguable, with clots forming when they are not medically necessary. For hemostasis measurements, T2MR is highly sensitive to changes in viscosity in a blood sample (such as clot formation, stabilization or dissipation), which alter the magnetic resonance signal and enable identification of clinically relevant hemostasis changes. The T2MR-based hemostasis platform is being developed to provide a wide range of hemostasis diagnostics, including measurements of platelet activity, fibrinolysis and clotting time, directly from a blood volume not more than a finger stick amount of blood sample.
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the performance of the Company's diagnostic products and the ability to bring such products to market. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. For more information on risk factors for
Media Contact:Susan Heins ,Pure Communications susan@purecommunicationsinc.com 864-286-9597 Investor Contact:Matt Clawson ,Pure Communications matt@purecommunicationsinc.com 949-370-8500